These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31698866)

  • 1. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.
    Scialla JJ; Lau WL; Reilly MP; Isakova T; Yang HY; Crouthamel MH; Chavkin NW; Rahman M; Wahl P; Amaral AP; Hamano T; Master SR; Nessel L; Chai B; Xie D; Kallem RR; Chen J; Lash JP; Kusek JW; Budoff MJ; Giachelli CM; Wolf M;
    Kidney Int; 2013 Jun; 83(6):1159-68. PubMed ID: 23389416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on fibroblast growth factor 23 in chronic kidney disease.
    Wolf M
    Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease.
    Kondo Y; Komaba H; Fukagawa M
    Expert Rev Mol Diagn; 2020 Jul; 20(7):715-724. PubMed ID: 32513031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
    Sakan H; Nakatani K; Asai O; Imura A; Tanaka T; Yoshimoto S; Iwamoto N; Kurumatani N; Iwano M; Nabeshima Y; Konishi N; Saito Y
    PLoS One; 2014; 9(1):e86301. PubMed ID: 24466013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fibroblast growth factor-23 in cardiorenal syndrome.
    Kovesdy CP; Quarles LD
    Nephron Clin Pract; 2013; 123(3-4):194-201. PubMed ID: 23942553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk.
    Pastor-Arroyo EM; Gehring N; Krudewig C; Costantino S; Bettoni C; Knöpfel T; Sabrautzki S; Lorenz-Depiereux B; Pastor J; Strom TM; Hrabě de Angelis M; Camici GG; Paneni F; Wagner CA; Rubio-Aliaga I
    Kidney Int; 2018 Jul; 94(1):49-59. PubMed ID: 29735309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages.
    Desjardins L; Liabeuf S; Renard C; Lenglet A; Lemke HD; Choukroun G; Drueke TB; Massy ZA;
    Osteoporos Int; 2012 Jul; 23(7):2017-25. PubMed ID: 22109743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.